Restless legs syndrome—current therapies and management of augmentation

  title={Restless legs syndrome—current therapies and management of augmentation},
  author={Claudia Trenkwalder and Juliane Winkelmann and Yuichi Inoue and Walter Paulus},
  journal={Nature Reviews Neurology},
Idiopathic restless legs syndrome (RLS) can severely affect quality of life and disturb sleep, so that pharmacological treatment is necessary, especially for elderly patients. [] Key Method In this Review, we summarize state-of-the-art therapies for RLS in the context of the diagnostic criteria and available guidelines, based on knowledge ranging from Class I evidence for the treatment of idiopathic RLS to Class IV evidence for the treatment of complications such as augmentation. We consider therapies…
Targinact for restless legs syndrome
  • Medicine, Biology
    Drug and Therapeutics Bulletin
  • 2016
The management of adults with RLS is reviewed, including the place of oxycodone/naloxone, in the treatment of severe to very severe RLS after failure of dopaminergic therapy.
[Update on restless legs syndrome].
Drugs approved for the treatment of RLS include dopaminergics (L-DOPA/benserazide) and dopamine agonists as well as oxycodone/naloxone, as a second-line treatment in severe cases.
Gabapentin treatment in clozapine-induced restless legs syndrome: two cases and a review of the literature
Clozapine-induced RLS in two patients with schizophrenia and its successful treatment with gabapentin, a nondopaminergic agent are described.
Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study.
Gabapentin Enacarbil: A Review in Restless Legs Syndrome
Overall, in short and longer-term trials, relatively few patients discontinued treatment, adverse events were mostly mild to moderate in severity, and somnolence/sedation and dizziness were the most commonly reported adverse events.
Restless legs syndrome augmentation among Japanese patients receiving pramipexole therapy: Rate and risk factors in a retrospective study
The RLS augmentation with PPX treatment in Japanese patients was occurred at rate of 9.1%, being quite compatible with previously reported rates in Caucasian patients, supporting the importance of keeping doses of PPX low throughout the RLS treatment course to prevent augmentation.


Treatment of Restless Legs Syndrome
  • C. Comella
  • Medicine, Psychology
  • 2013
Restless legs syndrome (RLS) is a common disorder diagnosed by the clinical characteristics of restlessness in the legs associated often with abnormal sensations that start at rest and are improved
Methadone for refractory restless legs syndrome
  • W. Ondo
  • Medicine, Psychology
    Movement disorders : official journal of the Movement Disorder Society
  • 2005
Methadone should be considered in RLS patients with an unsatisfactory dopaminergic response, and all patients who remain on methadone report at least a 75% reduction in symptoms, and none have developed augmentation.
Restless Legs Syndrome: Pathophysiology and Treatment
  • W. Ondo
  • Biology, Medicine
    Current Treatment Options in Neurology
  • 2014
Dopamine agonists may most robustly improve pure urge to move and certainly periodic limb movements and Mu specific opioids also robustly improved RLS and are probably underutilized in severe cases.
Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: an evidence-based review.
Evidence so far shows that both approaches may be effective in terms of reducing the RLS symptom's severity; nevertheless, more research is needed on the efficiency of treatments for uremic RLS.
Augmentation of the restless legs syndrome with carbidopa/levodopa.
A previously unreported but far more significant problem of markedly augmented RL symptoms occurred in the afternoon and the evening prior to taking the next nightly dose, and this augmentation was severe enough to require medication change for 50% of the RL patients and 13% of PLMS patients.